HTR1A and migraine disorder: Lasmiditan is a high-affinity and highly selective 5-hydroxytryptamine-1F agonist without significant action on the 5HT1A, 5HT1B, 5-HT2A, or 5HT1D receptors and is approved for the acute treatment of migraine with or without aura.